ARDT
Ardent Health, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+24/100
Last price
10.68
▲ 0.13 (1.23%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
10.55
Day high
10.84
Day low
10.49
Volume
290.30K
Market cap
$1.51B
P/E (TTM)
19.78
52W range
7.71 – 15.48
Trailing performance
Returnvs SPY
1W
+0.95%
-1.0%
1M
-2.11%
-3.3%
3M
+5.22%
+0.7%
6M
+18.40%
+0.2%
YTD
+20.95%
+6.7%
1Y
-23.82%
-40.2%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ARDT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
33.62M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | CASPERS DAVE Chief Executive Officer |
STOCK | 103.65K | $0 | Direct |
| Jun 5, 26 | LUMSDAINE ALFRED Chief Financial Officer |
BUY | 10.00K | $88.10K | Direct |
| Jun 5, 26 | DEMICHIEI ROBERT Director |
BUY | 11.26K | $98.30K | Direct |
| Apr 1, 26 | BYNOE PETER C B Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | GOODYEAR WILLIAM M Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | HAVDALA ELLEN Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | BONICK MARTIN Chief Executive Officer |
STOCK | 134.62K | $0 | Direct |
| Apr 1, 26 | LUMSDAINE ALFRED Chief Financial Officer |
STOCK | 53.85K | $0 | Direct |
| Apr 1, 26 | BULGARELLI PETER J Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | DEMICHIEI ROBERT Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | WEBB ROBERT THOMAS Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | CASPERS DAVE Chief Operating Officer |
STOCK | 35.67K | $0 | Direct |
| Apr 1, 26 | ROBINSON EDMONDO Director |
STOCK | 14.23K | $0 | Direct |
| Apr 1, 26 | SOTIR MARK R Chairman of the Board |
STOCK | 14.23K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BONICK MARTIN |
Chief Executive Officer | 1.44M | Stock Award(Grant) |
BYERS DAVID RAYNOR |
Officer | 130.44K | Stock Award(Grant) |
BYNOE PETER C B |
Director | 115.37K | Stock Award(Grant) |
CASPERS DAVE |
Chief Executive Officer | 174.93K | Stock Award(Grant) |
CHERNIN ETHAN |
Officer | 68.40K | Stock Award(Grant) |
GOODYEAR WILLIAM M |
Director | 115.37K | Stock Award(Grant) |
HAVDALA ELLEN |
Director | 115.37K | Stock Award(Grant) |
LUMSDAINE ALFRED |
Chief Financial Officer | 329.18K | Purchase |
PETROVICH STEPHEN C |
General Counsel | 1.15M | Stock Award(Grant) |
WEBB ROBERT THOMAS |
Director | 78.22K | Stock Award(Grant) |
Fundamentals
Market cap$1.51B
Enterprise value$3.44B
Revenue (TTM)$6.41B
Gross profit$3.74B
EBITDA$422.42M
Net income$78.23M
EPS (TTM)$0.54
Free cash flow$208.31M
Total cash$724.48M
Total debt$2.27B
Book value / share$9.52
Shares outstanding141.05M
Float21.76M
Short % of float14.77%
Dividend yield0.00%
Beta (5Y)0.72
Valuation & profitability ratios
Trailing P/E19.78
Forward P/E8.51
PEG ratio—
Price / sales—
Price / book1.12
EV / revenue0.54
EV / EBITDA8.14
Gross margin58.38%
Operating margin3.44%
Profit margin1.22%
Return on equity9.96%
Return on assets3.13%
Debt / equity130.19
Current ratio2.11
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.32B | $5.97B | $5.41B | $5.13B | +6.0% |
| Operating revenue | $6.20B | $5.86B | $5.32B | $5.03B | +5.9% |
| Cost of revenue | $3.74B | $3.57B | $3.38B | $3.37B | +4.8% |
| Gross profit | $2.58B | $2.40B | $2.03B | $1.76B | +7.7% |
| Selling, general & admin | $1.46B | $1.35B | $1.22B | $960.00M | +7.8% |
| Total operating expense | $2.26B | $1.99B | $1.81B | $1.55B | +13.3% |
| Operating income | $325.58M | $405.76M | $224.31M | $217.03M | -19.8% |
| Net interest income | -$55.20M | -$65.58M | -$74.31M | -$82.05M | +15.8% |
| Pre-tax income | $286.36M | $363.06M | $151.61M | $311.48M | -21.1% |
| Tax provision | $56.22M | $63.35M | $22.64M | $46.11M | -11.3% |
| Net income | $135.81M | $210.34M | $53.90M | $188.91M | -35.4% |
| Net income to common | $135.81M | $210.34M | $53.90M | $188.91M | -35.4% |
| Basic EPS | 0.96 | 1.59 | 0.38 | 1.34 | -39.6% |
| Diluted EPS | 0.96 | 1.58 | 0.38 | 1.34 | -39.2% |
| EBIT | $341.56M | $428.64M | $225.92M | $393.53M | -20.3% |
| EBITDA | $497.26M | $574.93M | $366.76M | $531.70M | -13.5% |
| Basic shares | 140.76M | 132.44M | 140.96M | 140.96M | +6.3% |
| Diluted shares | 141.45M | 132.74M | 140.96M | 140.96M | +6.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $709.60M | $556.78M | $437.58M | $456.12M | +27.4% |
| Cash & short-term investments | $709.60M | $556.78M | $437.58M | $456.12M | +27.4% |
| Accounts receivable | $686.10M | $743.03M | $775.45M | $603.36M | -7.7% |
| Inventory | $118.59M | $115.09M | $105.48M | $107.15M | +3.0% |
| Total current assets | $2.06B | $1.83B | $1.62B | $1.41B | +12.3% |
| Property, plant & equipment | $2.14B | $2.04B | $2.01B | $1.99B | +5.1% |
| Goodwill & intangibles | $968.79M | $929.01M | $921.63M | $921.63M | +4.3% |
| Total assets | $5.29B | $4.96B | $4.73B | $4.48B | +6.7% |
| Total current liabilities | $1.05B | $945.42M | $994.10M | $808.60M | +10.7% |
| Current debt | $23.44M | $9.23M | $18.61M | $16.09M | +153.9% |
| Long-term debt | $1.08B | $1.09B | $1.17B | $1.16B | -0.9% |
| Total debt | $2.32B | $2.28B | $2.40B | $2.39B | +1.6% |
| Total liabilities | $3.61B | $3.43B | $3.65B | $3.43B | +5.0% |
| Retained earnings | $501.61M | $365.80M | $155.45M | $101.55M | +37.1% |
| Shareholder equity | $1.29B | $1.13B | $0 | $0 | +13.8% |
| Working capital | $1.01B | $887.33M | $623.98M | $600.65M | +14.1% |
| Net tangible assets | $319.11M | $202.36M | -$921.63M | -$921.63M | +57.7% |
| Shares issued | 142.86M | 142.75M | 140.96M | 140.96M | +0.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $230.13M | $299.71M | $128.98M | $265.37M | — | -23.2% |
| Depreciation & amortisation | $155.70M | $146.29M | $140.84M | $138.17M | — | +6.4% |
| Stock-based compensation | $39.29M | $17.98M | $904.00K | $611.00K | — | +118.6% |
| Change in working capital | -$3.34M | -$181.75M | -$56.31M | -$9.74M | — | +98.2% |
| Operating cash flow | $470.51M | $315.03M | $221.70M | -$38.36M | — | +49.4% |
| Capital expenditure | -$211.90M | -$187.51M | -$137.41M | -$151.11M | — | -13.0% |
| Investing cash flow | -$214.23M | -$220.46M | -$137.98M | $46.58M | — | +2.8% |
| Dividends paid | — | $0 | $0 | -$174.81M | -$62.13M | — |
| Financing cash flow | -$103.47M | $24.64M | -$102.26M | -$270.33M | — | -519.9% |
| Free cash flow | $258.61M | $127.52M | $84.29M | -$189.47M | — | +102.8% |
| End cash position | $709.60M | $556.78M | $437.58M | $456.12M | — | +27.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.62B | $1.60B | $1.61B | $1.58B | $1.65B | — | +1.3% |
| Operating revenue | $1.60B | $1.58B | $1.57B | $1.54B | $1.62B | — | +0.7% |
| Cost of revenue | $955.81M | $929.98M | $928.92M | $952.84M | $942.34M | — | +2.8% |
| Gross profit | $666.44M | $671.89M | $676.16M | $623.90M | $702.94M | — | -0.8% |
| Selling, general & admin | $394.49M | $382.84M | $376.24M | $369.57M | $362.66M | — | +3.0% |
| Total operating expense | $610.67M | $590.97M | $571.40M | $607.45M | $565.66M | — | +3.3% |
| Operating income | $55.77M | $80.91M | $104.75M | $16.46M | $137.28M | — | -31.1% |
| Net interest income | -$12.57M | -$12.21M | -$12.38M | -$13.91M | -$14.73M | — | -2.9% |
| Pre-tax income | $43.20M | $74.59M | $92.37M | -$2.20M | $121.99M | — | -42.1% |
| Tax provision | $8.51M | $16.10M | $18.11M | -$3.41M | $26.29M | — | -47.1% |
| Net income | $16.90M | $39.85M | $44.96M | -$23.48M | $72.95M | — | -57.6% |
| Net income to common | $16.90M | $39.85M | $44.96M | -$23.48M | $72.95M | — | -57.6% |
| Basic EPS | 0.12 | 0.28 | — | -0.17 | 0.52 | 0.30 | -57.1% |
| Diluted EPS | 0.12 | 0.28 | — | -0.17 | 0.52 | 0.29 | -57.1% |
| EBIT | $55.77M | $86.80M | $104.75M | $11.71M | $136.72M | — | -35.7% |
| EBITDA | $97.11M | $129.79M | $145.79M | $50.87M | $176.03M | — | -25.2% |
| Basic shares | 141.69M | 141.27M | — | 141.23M | 140.37M | 140.06M | +0.3% |
| Diluted shares | 143.05M | 141.78M | — | 141.23M | 141.52M | 140.70M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $724.48M | $609.69M | $709.60M | $609.44M | $540.63M | +18.8% |
| Cash & short-term investments | $724.48M | $609.69M | $709.60M | $609.44M | $540.63M | +18.8% |
| Accounts receivable | $695.95M | $685.99M | $686.10M | $729.41M | $758.64M | +1.5% |
| Inventory | $116.02M | $119.84M | $118.59M | $121.59M | $118.40M | -3.2% |
| Total current assets | $2.05B | $2.02B | $2.06B | $1.96B | $1.88B | +1.7% |
| Property, plant & equipment | $2.13B | $2.14B | $2.14B | $2.10B | $2.07B | -0.6% |
| Goodwill & intangibles | $966.94M | $967.60M | $968.79M | $967.60M | $954.61M | -0.1% |
| Total assets | $5.28B | $5.25B | $5.29B | $5.15B | $5.03B | +0.5% |
| Total current liabilities | $976.32M | $951.48M | $1.05B | $943.15M | $880.87M | +2.6% |
| Current debt | $28.57M | $37.63M | $23.44M | $19.34M | $19.33M | -24.1% |
| Long-term debt | $1.07B | $1.07B | $1.08B | $1.09B | $1.09B | +0.0% |
| Total debt | $2.27B | $2.29B | $2.32B | $2.28B | $2.27B | -0.8% |
| Total liabilities | $3.54B | $3.52B | $3.61B | $3.52B | $3.38B | +0.5% |
| Retained earnings | $558.36M | $541.46M | $501.61M | $456.65M | $480.13M | +3.1% |
| Shareholder equity | $1.35B | $1.34B | $1.29B | $1.24B | $1.25B | +1.0% |
| Working capital | $1.08B | $1.07B | $1.01B | $1.01B | $996.24M | +0.9% |
| Net tangible assets | $383.61M | $369.23M | $319.11M | $270.62M | $299.98M | +3.9% |
| Shares issued | 141.91M | 143.13M | 142.86M | 143.17M | 143.10M | -0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $34.69M | $58.49M | $74.26M | $1.21M | $95.70M | -40.7% |
| Depreciation & amortisation | $41.34M | $42.99M | $41.04M | $39.16M | $39.31M | -3.8% |
| Stock-based compensation | $7.95M | $8.93M | $9.11M | $9.67M | $11.25M | -10.9% |
| Change in working capital | $107.53M | -$160.13M | $69.14M | $83.06M | -$28.04M | +167.2% |
| Operating cash flow | $196.74M | -$60.22M | $223.44M | $154.37M | $117.49M | +426.7% |
| Capital expenditure | -$38.68M | -$28.09M | -$84.00M | -$58.80M | -$46.20M | -37.7% |
| Investing cash flow | -$39.18M | -$27.90M | -$86.23M | -$58.63M | -$46.25M | -40.4% |
| Financing cash flow | -$42.77M | -$11.79M | -$37.05M | -$26.93M | -$25.66M | -262.9% |
| Free cash flow | $158.06M | -$88.31M | $139.44M | $95.57M | $71.29M | +279.0% |
| End cash position | $724.48M | $609.69M | $709.60M | $609.44M | $540.63M | +18.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
15.00
Positioning, not flow
Max pain
12.50
+17.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
10.00
2 contracts
Heaviest put OI
10.00
20 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.27 | +44.0% |
| Mar 2026 | 0.18 | 0.30 | +68.2% |
| Dec 2025 | 0.35 | 0.36 | +4.5% |
| Sep 2025 | 0.42 | 0.83 | +95.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.25 | 4 | $1.60B | +1.7% |
| Next quarter | 0.35 | 4 | $1.63B | +1.7% |
| Current year | 1.09 | 4 | $6.46B | +2.2% |
| Next year | 1.26 | 4 | $6.73B | +4.1% |
Analyst targets & ownership
Mean target$12.67
High target$14.00
Low target$10.50
Implied upside18.60%
Analyst count12
ConsensusBUY
Strong buy / Buy1 / 6
Hold5
Sell / Strong sell0 / 1
Held by insiders23.84%
Held by institutions76.71%
Institutions holding186
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.49
+1.84% from price
SMA 20
10.65
+0.26% from price
SMA 50
10.85
-1.56% from price
SMA 100
10.28
+3.93% from price
SMA 200
9.72
+9.87% from price
EMA 12
10.55
+1.27% from price
EMA 26
10.64
+0.35% from price
EMA 50
10.62
+0.52% from price
RSI (14)
50.8
Neutral
MACD (12,26,9)
-0.10
Hist -0.00
ATR (14)
0.35
3.30% of price
Realised vol 30D
26.1%
Annualised
Bollinger upper
11.12
20, 2σ
Bollinger lower
10.18
20, 2σ
50 / 200 cross
Golden
10.85 vs 9.72
Trend bias
Above 200
+9.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.10
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
26.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.5%
Peak to trough
Max drawdown 5Y
-61.2%
Peak to trough
ATR 14
0.35
3.30% of price
Beta (reported)
0.72
5Y monthly, from filing
Short interest
Shares short
4.58M
Prior 4.14M
Change vs prior
+10.4%
Shorts adding
% of float
14.77%
Elevated
% of shares out
3.24%
Against total outstanding
Days to cover
12.1
Crowded exit
Float
21.76M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 26 | BMO Capital | INITIATED | — | Market Perform |
| Sep 18, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Aug 10, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 14, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jul 9, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 7, 26 | UBS | MAINTAINED | Buy | Buy |
| Mar 10, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Mar 6, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Jan 20, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Dec 18, 25 | UBS | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-04
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-26
Periodic Financial Reports
10-Q · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-05-05
Headlines
Ardent Health's Divestment of St. Francis Campus Shows Asset's ROI Below Expectations, UBS Says
MT Newswires · 6d ago
Ardent Health to Transfer Full Ownership of St. Francis Campus
MT Newswires · 8d ago
The University of Kansas Health System and Ardent Health Announce Plans to Transition Ownership of St. Francis Campus
Business Wire · 8d ago
BMO Capital Initiates Ardent Health With Market Perform Rating, $11 Price Target
MT Newswires · 14d ago
Is the Options Market Predicting a Spike in Ardent Health Stock?
Zacks · 21d ago
Ardent Health Hospitals Earn Recognition in U.S. News & World Report’s 2026-2027 Best Hospitals Rankings
Business Wire · 22d ago
HealthStream Defines a New Enterprise Category Alongside the EHR and ERP, the Enterprise Clinical Workforce Platform (ECWP)
Business Wire · 23d ago
Ardent Health Marks Expansion of Specialty Care in New UT Tyler School of Medicine
Business Wire · 35d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.